Concepedia

Author

Serban Ghiorghiu

AstraZeneca (United Kingdom)ORCID

Also Known As

S Ghiorghiu, S. Ghiorghiu, Serban Ghiorghiu

65

Publications

10.7K

Citations

17

H-Index

35

Concepts

All Affiliations

AstraZeneca (United Kingdom)Seoul National University HospitalEmory UniversityDana-Farber Cancer InstituteNational Taiwan University Hospital
SG

About

Serban Ghiorghiu is an author at AstraZeneca (United Kingdom) specializing in medicine, cancer therapeutics, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

912

2

Health Sciences

4

4

188

3

Public Health

1

1

14

4

Cell Biology

1

1

21

5

Health Informatics

1

1

14

Serban Ghiorghiu

×

20

Publications

10.6K

Citations

16

H-Index

YearCitations

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn,

New England Journal of Medicine

2016

3.2K

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu,

Cancer Discovery

2014

2.2K

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim,

New England Journal of Medicine

2015

2.1K

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd,

The Lancet Oncology

2016

632

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim,

Journal of Clinical Oncology

2017

563

Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee,

Journal of Clinical Oncology

2017

523

Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer

Tony Mok, Yi‐Long Wu, M. Ahn,

QUT ePrints (Queensland University of Technology)

2017

474

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

J.S.W. Stewart, Ezra E.W. Cohen, Lisa Licitra,

Journal of Clinical Oncology

2009

379

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

Lucio Crinò, Federico Cappuzzo, Petr Zatloukal,

Journal of Clinical Oncology

2008

217

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).

Pasi A. Jänne, Suresh S. Ramalingam, James Chih‐Hsin Yang,

Journal of Clinical Oncology

2014

139

Page 1